The latest filing does not contain sufficient reviewed comparable structured data
Last SEC check
Sep 14, 2026
Filing → research
2 min
Data basis
Official SEC · no quote feed
Component status
Filing EvidenceResearch CurrentOfficial SEC filing history is available
Structured FinancialsSource LimitedThe latest filing model has no reviewed comparable financial mapping · XBRL_DATE_OUT_OF_RANGE
Filing AnalysisSource LimitedNo filing analysis job is currently running · XBRL_DATE_OUT_OF_RANGE
Fundamental StateSource LimitedFundamental State depends on validated comparable financial metrics · XBRL_DATE_OUT_OF_RANGE
RESEARCH SNAPSHOTTENAX THERAPEUTICS, INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
INSIDER STATE / 90DRecent disclosed activity
Open-market purchases
0
Sales
0
Distinct buyers
0
Repeat buyer
NO
Conservative Form 4 classification · not a sentiment label
Flagship analysis / V3
What changed?
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q0001193125-26-32745513 governed changes · top 7 shown
01
HIGH IMPORTANCEShare CountShare Dilution100TH HISTORICAL PCTL · N=8
Shares outstanding increased 720.3%
Shares outstanding changed +720.3% from the comparable as-filed period. The change ranks at the 100th percentile of 8 prior comparable changes.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.